Company Profile
PMV Pharmaceuticals Stock Price, News & Catalysts
- Ticker:
- PMVP
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.46 USD (+2.10%)
Close
Last updated: September 17, 2026
62.9M USD
Market cap
Why the stock is moving
As of Sep 17, 2026, PMVP closed up 2.10% at $1.46. No new same-company headline was identified in the current news window.
Company overview
Mutant-p53 Precision Oncology
PMV Pharmaceuticals develops small-molecule precision therapies that target specific mutations in the p53 tumor-suppressor protein. Its platform is designed to restore the normal cancer-suppressing function of structurally altered p53 proteins, addressing mutations found across multiple solid-tumor types.
Rezatapopt
Rezatapopt, formerly PC14586, is a first-in-class p53 reactivator that selectively binds the pocket created by the TP53 Y220C mutation. Binding is intended to stabilize the mutant protein and restore wild-type p53 tumor-suppressor activity. The candidate has received FDA Fast Track designation for locally advanced or metastatic TP53 Y220C-mutated solid tumors and Orphan Drug designation in ovarian, fallopian-tube, and primary peritoneal cancers.
PYNNACLE Registrational Program
The Phase 1/2 PYNNACLE study evaluates oral rezatapopt in advanced solid tumors harboring TP53 Y220C. Its registrational Phase 2 portion includes ovarian, lung, breast, endometrial, and other solid-tumor cohorts, while the primary accelerated-approval strategy is focused on platinum-resistant or refractory ovarian cancer.
Tumor-Agnostic Development Potential
Because TP53 Y220C occurs across multiple cancers, PMV is developing rezatapopt as a mutation-defined rather than organ-defined therapy. The broader PYNNACLE basket structure provides a path to assess activity across several tumor types while the ovarian-cancer cohort supports the initial regulatory filing.
Future catalysts
- Submission of the rezatapopt NDA for accelerated approval in TP53 Y220C-mutated platinum-resistant or refractory ovarian cancer in the first quarter of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of PMV Pharmaceuticals (PMVP)?
PMV Pharmaceuticals (PMVP) most recently closed at 1.46 USD, a +2.10% move versus the previous session.
What is the market cap of PMV Pharmaceuticals (PMVP)?
PMV Pharmaceuticals currently has a market capitalization of 62.9M USD on BioPharmSignal.
What does PMV Pharmaceuticals do?
Mutant-p53 Precision Oncology PMV Pharmaceuticals develops small-molecule precision therapies that target specific mutations in the p53 tumor-suppressor protein. Its platform is designed to restore the normal cancer-suppressing function of structurally altered p53 proteins, addressing mutations found across multiple solid-tumor types. Rezatapopt Rezatapopt,...
On which exchange is PMVP stock listed?
PMV Pharmaceuticals (PMVP) is associated with NASDAQ, United States, Biopharma.
What is Mutant-p53?
Mutant-p53 Precision Oncology PMV Pharmaceuticals develops small-molecule precision therapies that target specific mutations in the p53 tumor-suppressor protein.
Which conditions is PMV Pharmaceuticals targeting with Mutant-p53?
PMV Pharmaceuticals is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does PMV Pharmaceuticals describe recent progress with Mutant-p53?
Submission of the rezatapopt NDA for accelerated approval in TP53 Y220C-mutated platinum-resistant or refractory ovarian cancer in the first quarter of 2027.
What is Precision?
Mutant-p53 Precision Oncology PMV Pharmaceuticals develops small-molecule precision therapies that target specific mutations in the p53 tumor-suppressor protein.